Physician profile
Avraham Belizon
NPI 1164687893
$482,410.45
in general payments reported to CMS, 2019-2025
18 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $25K · 2021: $65K · 2022: $119K · 2023: $94K · 2024: $64K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $126K · Travel and Lodging: $52K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,225 · Food and Beverage: $2,814 · Gift: $83.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $126,335.41 |
| Travel and Lodging | $51,956.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,225.00 |
| Food and Beverage | $2,814.37 |
| Gift | $83.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $473,883.17 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Baxter Healthcare | $6,393.01 | 2021-2024 | Perclot |
| Davol INC. | $516.87 | 2021-2025 | Phasix Mesh |
| Janssen Biotech, INC. | $275.00 | 2023-2024 | Stelara, Tremfya |
| Medtronic, INC. | $259.48 | 2023-2025 | Endoflip, Transorb, Interstim |
| Endogastric Solutions, INC | $187.46 | 2022 | |
| Atricure, INC. | $165.04 | 2023 | |
| Gilead Sciences, INC. | $141.88 | 2025 | Livdelzi |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Enterra Medical, INC. | $118.80 | 2024 | |
| Axonics, INC. | $113.42 | 2021-2024 | Axonics |
| Becton, Dickinson and Company | $96.67 | 2020 | |
| Braintree Laboratories, INC. | $46.87 | 2020-2021 | |
| Heron Therapeutics, INC. | $25.61 | 2021 | |
| Innovation Technologies INC | $23.15 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $22.03 | 2022 | |
| Boston Scientific Corporation | $16.99 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$850,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avraham Belizon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.